Preferred Label : N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide;

MeSH note : a Janus kinase 1 and Janus kinase 2 inhibitor; structure in first source;

CISMeF synonym : CYT 387;

MeSH synonym : Momelotinib;

MeSH hyponym : CYT387; CYT-387;

Is substance : O;

UNII : 6O01GMS00P;

Details


Main resources

You can consult :


https://ansm.sante.fr/tableau-acces-derogatoire/momelotinib
2024
false
false
false
France
French
drug information
N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide

---
https://www.ema.europa.eu/en/medicines/human/EPAR/omjjara
2023
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
orphan drug production
N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide
N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide
momelotinib
drug approval
europe
splenomegaly
adult
primary myelofibrosis
risk management
product surveillance, postmarketing
Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase
Post-Essential Thrombocythemia Myelofibrosis
administration, oral
pregnancy
breast feeding
drug interactions
Janus Kinase Inhibitors
Janus Kinase Inhibitors
JAK1 Inhibitor
JAK2 Inhibitor
drug evaluation, preclinical

---
https://www.has-sante.fr/jcms/p_3478261/fr/omjjara-momelotinib-splenomegalie-et-symptomes-chez-les-patients-adultes-atteints-de-myelofibrose
2023
false
false
false
France
administration, oral
anemia
Secondary Myelofibrosis
Janus Kinase Inhibitors
momelotinib
evaluation of the transparency committee
splenomegaly
adult
N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide
Myelofibrosis

---
Nous contacter.
15/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.